Introduction
Cervical cancer is the fourth most common cancer in women, and the seventh overall, with an estimated 528,000 new cases and 266,000 deaths worldwide in 2012. More than 88% of the deaths occur in low-income countries and that percentage is predicted to reach 91.5% by 2030. (1) . According to the latest data from GLOBOCAN study, the incidence of cervical cancer in Serbia is 23.8 per 100,000 and among the European countries it is ranked fourth, after Romania, Lithuania, and Bulgaria. Currently, with 1501 new cases and approximately 609 deaths per year, cervical cancer is the fifth cause of death from cancer among Serbian women. The values of the incidence rate of cervical cancer in Serbia are still among the highest and approximately twice the average incidence rate in Europe (11.2 to 100,000) (2) . Furthermore, cervical cancer is the second most common female cancer in women aged 15 to 44 years in Serbia (3).
It is well known that human papilloma virus (HPV) infection plays a major role in the development of cervical cancer. HPV carcinogenicity has been convincingly established for cervical cancer and it is generally accepted that HPV infection is a necessary prerequisite for the development of invasive cervical cancer (ICC). More than 40 types of HPV can infect the anogenital tract (4) . The most common types of HPV that can be found in cancers belong to phylogenetically different branches of the genus Alpha. The International Agency for Research on Cancer has classified HPV 16 and 18 as human cervical carcinogens since 1995 (5) . By 2011 the group was expanded to include HPV 31, 33, 35, 39, 45 , 51, 52, 56, 58, and 59 (6) . It is estimated that over 50%-80% of sexually active women will be infected with one or more genital HPV types during their lives, with a peak prevalence in young sexually active individuals (7) .
The introduction of prophylactic vaccines represents significant progress in the prevention of cervical cancer. HPV prophylactic vaccines are using virus like particles (VLPs). Currently licensed HPV vaccines, a bivalent (Cervarix) and a quadrivalent HPV vaccine (Gardasil), both protect against HPV types 16 and 18. In addition, Gardasil protect against HPV 6 and 11, which cause close to 90% of external genital wart cases (8) . Longterm studies have shown that besides HPV 16 and 18, acknowledged as the most frequently detected types in ICC worldwide, HPV types 31, 33, 35, 45, 52, and 58 are also frequently present. That was the starting point for the development of a new recombinant 9-valent vaccine by Merck, code named V503, that also uses VLPs. V503 contains 5 additional HPV types (31, 33, 45, 52 , and 58) to the four HPV types previously included in Gardasil, and has successfully completed several studies. Phase III studies are ongoing (9) . However, in different parts of the world some other oncogenic types play important roles in the development of premalignant and malignant changes. In order to estimate the effectiveness of a prospective vaccination, prior assessment of the prevalence of HPV genotypes and the heterogeneity of their distribution in the population involved is needed. Region-specific differences have already been detected (10, 11) . However, there are still certain parts of the world lacking such important data, Serbia being one of them (3) . With this in mind, we have undertaken the present study.
The goal of this study was to determine the presence and age distribution of different oncogenic HPV types in a population of women in the South Backa region and their relationship to the results of Pap tests.
Materials and methods

Study design
Ethical approval for all study protocols was received from the Institute of Public Health of Vojvodina, Novi Sad, Serbia. The frequency of oncogenic HPV types was analyzed in a sample of 1087 women (ages 18-65 years, with a mean age of 35.9 years). The sample consisted of women attending gynecological outpatient clinics for regular gynecologic control at the Department of Obstetrics and Gynecology, Clinical Center of Vojvodina, Novi Sad, Serbia. Both women with normal and abnormal Pap smears were sent for the virological diagnosis of HPV infection. The subjects were grouped according to diagnosis. The study group consisted of 307 women with atypical squamous cells of undetermined significance (ASCUS), 97 women with low grade squamous intraepithelial lesions (LSIL), 40 women with high grade squamous intraepithelial lesions (HSIL), and 643 women with normal cytology. 
Cervical cytology
Statistical analysis
The observed data were statistically processed by twoway ANOVA, for each individual type of HPV. Two factors were examined: age and cytological diagnosis. Analysis of variance and LSD tests were performed on data transformed by arcsine transformation in order to meet normal distribution of frequencies. Results were considered significant if the probability was less than 0.05.
Results
A total of 1087 women were involved in the study. The age of the patients ranged between 18 and 65 years (with a mean age of 35.9 years). The age-specific distribution was as follows: <30 years (a mean age of 26.1), 30-39 years (a mean age of 35.1), 40-49 years (a mean age of 45.1), and ≥50 years (a mean age of 55.5).
Following the collection of data on HPV DNA genotypes, the samples were examined for the presence of individual types. Overall, 50.5% of the women were HPV positive. HPV DNA was positive in 36.4% of the women with normal cervical cytology, in 66.7% of those with ASCUS, in 82.3% of those with LSIL, and in 97.0% of those with HSIL, as shown in Figure 1 .
The results of the LSD test show that the proportion of HPV positivity increased with the increase of cytological abnormality, and decreased with age. The observed differences were statistically significant among all examined cytological diagnoses. However, the results of the LSD test showed that the smallest percentage of HPV infected women was in the oldest age group (≥50, 56.4%), while the differences among the other age groups (<30, 30-39, and 40-49) were not significant (75.8%, 65.7%, and 58.5% respectively), as shown in Figure 2 .
Following the collection of data on HPV DNA genotypes, the samples were examined for the presence of individual types. In all samples positive for HPV DNA, the distribution of HPV types was as follows: HPV 16 (37.3%), HPV 31 (31.7%), HPV 51 (15.5%), HPV 52 (12.6%), HPV 18 (10.7%), HPV 56 (9.8%), HPV 45 (9.3%), HPV 33 (8.4%). HPV 58 (8.0%), HPV 59 (7.3%), HPV 39 (6.2%), and HPV 35 (4.7%) ( Figure 3 ). Multiple HPV infections were found in 36.2%.
The significance of influence of controlled sources of variation (age, cervical cytology, and the interaction of age × cervical cytology) was examined by two-way ANOVA.
Results of the F-test show that the presence of HPV types 18, 31, 33, 51, 58, and 59 was significantly influenced by age, while the presence of HPV types 16 and 45 was significantly influenced by cervical cytology as shown in Table 1 .
A wide spectrum of high risk HPV was found among women with normal cytology and women with a low grade cervical lesion rate (ASCUS and LSIL). The most prevalent HPV types found were 16, 31, 51, 18, and 52. In the HSIL group the most prevalent HPV types were 16 and 45. The increase of the presence of these types clearly followed the increase of the degree of cytological damage as shown in Tables 2 and 3 .
Discussion
This study presents results of the distribution of 12 oncogenic types of HPV among a nonvaccinated sample of 1087 women (18-65 years old, with a mean age of 35.9) in the South Backa region of Serbia. The study was conducted during an opportunistic screening program that was conducted in Serbia. Overall, the HPV prevalence (about 50.5%) is very high because women with both normal and abnormal cytology were included. Although HPV infection can cause cytological abnormalities, the prevalence of HPV in women with normal cytological Evident variations in HPV rates can be explained by differences in the age range, representation of cytological diagnosis in the studied groups, the sensitivity of the DNA assay used for the detection of HPV infection, and the duration of the study. The results of HPV positivity among different age groups show that the highest percentage of infection was present in the youngest women, namely 20-29 years of age (75.8%), while in the oldest age group (50 years of age) 56.4% of the women were infected. Studies conducted among women from 15 areas in four continents revealed substantial variations in the shape of the age-specific curves of HPV prevalence (18) . In our study a decline of HPV prevalence in the group above 50 years of age was observed, while in a few studies from Asia, besides an HPV peak in the youngest age group, a second peak was observed in the older women. In contrast, in the rural areas of Asia and in Nigeria the HPV prevalence was similar in all age groups (19) .
One of the goals of our study was the analysis of individual HPV types in relation to age and cytology results. The results showed that members of the alpha-9 HPV species, particularly HPV16 (found in 37.3%) and HPV31 (found in 31.7%), were the most prevalent HPV genotypes in our region. Additionally, 15.5% of the infections were caused by the HPV51, a member of the alpha-5 HPV species.
According to the results of many studies, HPV16 is the most prevalent type worldwide, but its frequency in geographically and ethnically diverse populations of women worldwide is different (13) . When we studied the association of HPV16 with age and cytological diagnosis, it was observed that this type of virus was widespread in all (20) .
In the studied women of the South Backa region, besides HPV 16, HPV type 31 is also abundant. HPV31 was represented in all age groups, but was more common in younger women (17.1% in the 20-29 age group vs. 3.1% in women older than 50 years). We did not find a statistically significant influence of HPV31 on the cytological results. According to a metaanalysis study conducted on five continents, HPV31 is especially frequent in Europe (21) . HPV31 is considered the fourth most common HPV type in squamous cervical carcinomas and in asymptomatic patients worldwide (13) . The remaining investigated members of alpha-9 species (HPV 33, 35, 52, and 58) were present in a low percentage in the studied region. In our study HPV33 and HPV35 were more often found in younger women and in ASCUS/LSIL cytology. However, new data from the study of Sanjose et al. indicate that in Europe HPV33 is responsible for 4% and HPV35 for 2% of cervical carcinomas (11) . HPV52 and HPV58 are typical for regions of Asia, where both of them cause invasive cervical carcinomas more frequently than in other world regions (22) . In our research, the frequencies of HPV52 and 58 were about 10%, with no statistically significant influence of age and cytology on their variation.
The surprising fact is a conspicuously high prevalence of HPV51 in the South Backa region. Research conducted by Piana et al. confirmed the high prevalence of HPV51 infection among women with cervical dysplasia and invasive disease in North Sardinia, Italy (23) . This was the first study pointing out such a strong association between HPV51 and invasive cervical cancer. Recent epidemiological studies show high HPV51 frequency in several geographical areas of Europe, and among them is the eastern Mediterranean. In a German population study of young women, HPV51 was ranked second after HPV16 (24) , and similar data were observed in the Netherlands (25) . Among Turkish women, HPV51 is ranked third (26) . In Bosnia and Herzegovina, Croatia, Czech Republic, France, Greece, Italy, the Netherlands, Poland, Portugal, and Spain HPV51 has been detected in only 1% of the cases of cervical cancer (11) . Although in our research it was found that the prevalence of HPV51 decreased with age, there were no significant differences in its prevalence in relation to cytological abnormality groups. These data suggest that the presence of this type could not be related to the cancer incidence in our region. However, taking into account the results of research in other regions (23, 25) , the confirmation of this claim requires a study on a larger number of subjects. Still, data on the prevalence of HPV51 are especially important since currently commercially available vaccines and second generation nanovalent prophylactic HPV vaccines do not protect against HPV51 (9, 23) .
Numerous studies conducted in the world show that representatives of the alpha-7 species (HPV 18, 45, and 59) are responsible for 15% of invasive cervical cancers and that they are strongly associated with adenocarcinoma of the cervix (18) . All members of this group were found in a low percentage in our research. Similar to some European studies, we found that in our region HPV18 was present at a lower percentage and its frequency was five times lower than that of HPV16 (27) . Furthermore, if we consider the distribution of HVP genotypes in the Balkan countries (Table 4) , it could clearly be seen that the frequency of HPV 18 ranks fourth or fifth in most countries, enabling us to label it as a regional characteristic (16, (28) (29) (30) (31) (32) (33) (34) (35) . Although many studies clearly state that the presence of HPV18 increases with the severity of cytological lesions (18, 21) , we found it in 1.41%, 3.74%, 4.03%, and 3.63% of the NILM, ASCUS, LSIL, and HSIL groups, respectively, with no statistical significance in the differences among them. The low percentage of HPV18 in the HSIL group could be a consequence of the low frequency of adenocarcinoma of the cervix in the analyzed sample, taking into account that in our research women with this diagnosis (adenocarcinoma) were not specifically targeted. In order to reach reliable conclusions, we think that research should be conducted on a larger scale.
In our study, HPV45 was detected rarely in women with normal and ASCUS cytology. Furthermore, we found that HPV45 behaved similarly to HPV16, and the incidence of both of them significantly increased with the severity of the cytological lesions. A retrospective crosssectional study conducted in 38 countries in Europe, North America, Central and South America, Africa, Asia, and Oceania, found that the mean age of patients with cervical cancer is the lowest for HPV45 (46.8 years), followed by HPV18 (48.2 years), and HPV16 (50.0 years) (36) .
We observed that the prevalence of HPV59 decreased with age, without a statistically significant influence on cytology. The remaining member of the alpha-7 genus, HPV39, was present in less than 5% of the studied women, without a statistically significant influence of age and cytology. The last researched HPV type was HPV56, which belongs to the alpha-6 HPV species. According to the analysis results of 3085 cervical carcinomas, HPV56 accounted for 1.2% of all cases worldwide (10) . In our study, the frequency of HPV56 was 9.8%, and we found a mild statistically significant influence of age, without a statistically significant influence on cytology.
We observed that multiple HPV infections were detected in 36.2% of all samples, and were more frequent in women younger than 30 years. The overall prevalence of multiple infections was higher than the one observed by other authors (25.6%) from Serbia (16) , and can be attributed to differences in the samples selected for the studies. While the patients analyzed in the work of Knezevic et al. (16) consisted of women with normal Pap results only, our sample included women with abnormal cytology as well, meaning that those women already had some problems and were referred to HPV testing subsequently. The observation that multiple infections are more frequent in younger women is consistent with the results of many authors (20) , and supports the fact that greater sexual activity in younger women may be associated with the transmission of multiple HPV types. Still, among younger women HPV infections often have a transitory character. In our study, a coinfection by HPV 31 and 51 was found often. The question is whether multiple infections mean a higher risk for cancer. One decade ago there was a view that cervical neoplasia is the result of clonal expansion of a cell infected with a single type of HPV (37) . Some more recent research investigated the importance of multiple infections for carcinogenesis. Quint et al. examined the distribution of multiple HPV infections in CIN lesions by the laser capture microdissection PCR method and concluded that every HPV type found in CIN is associated with a biologically separate and independent CIN lesion (38) .
The present work provides new data on the circulation of oncogenic HPV genotypes and the frequency of multiple infections among women in Vojvodina, Serbia. These data suggest that a prophylactic vaccine against HPV 16 and 18 has the potential to prevent approximately half of the highgrade lesions. From the standpoint of designing a second generation prophylactic HPV vaccines, it is important to know the distribution of the most frequent oncogenic human papillomavirus (HPV) in the population of certain regions. Taking into account the variety of genotypes, future therapeutic HPV vaccines would have greater potential benefits if their design for treating HPV infections were not restricted to HPV 16 and 18 only.
In the end, it is important to note that future wide-scale HPV screening and research in Serbia is necessary, since reliable data on specific HPV genotypes present in the population would be valuable not only as a starting point for the implementation of a vaccination program, but also as a critical step in the algorithm of cancer diagnosis and treatment of individual patients. *Results vary with respect to the sample size, methods used, and criteria for sample selection. In order to obtain more reliable and plausible comparisons, close to uniform study protocols are needed.
